Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04798274
Recruitment Status : Recruiting
First Posted : March 15, 2021
Last Update Posted : August 19, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )

Brief Summary:

Background:

Autism spectrum disorder (ASD) is a complex neurodevelopmental syndrome. Researchers think brain development may be controlled by gamma-aminobutyric acid (GABA). They want to learn how abnormalities in the GABA system may contribute to ASD.

Objective:

To see if repetitive transcranial magnetic stimulation (rTMS) creates short-term changes in how different parts of the brain communicate.

Eligibility:

Right-handed people ages 14-17 with ASD, and healthy volunteers ages 18-25.

Design:

Participants will be screened with:

Medical history

Physical exam

Medicine review

Neurological exam

Psychological tests and rating scales

Forms and surveys.

Participants will have a hearing test and ear exam.

Participants will have magnetic resonance imaging (MRI) of the brain. They will lie on a table that moves in and out of the MRI scanner. They may look at a screen while in the scanner. A coil will be placed over their head.

Participants will have magnetic resonance spectroscopy. It takes pictures of chemicals in the brain using the MRI scanner.

Participants will have magnetoencephalography. They will sit in a chair. A helmet with magnetic field sensors will be placed on their head.

Participants will have TMS. A wire coil will be held on their scalp. A brief electrical current will pass through the coil.

Participants will have electromyography. Sticky pad electrodes will be placed on the skin during TMS. The electrical activity of their muscles will be measured.

Participants will have rTMS. It uses short bursts of magnetic pulses to affect brain activity.

ASD participants will have 6 visits over 6 8 weeks. Healthy volunteers will have 3 visits over 3-4 weeks....


Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Device: Transcranial Magnetic Stimulation Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Actual Study Start Date : June 15, 2021
Estimated Primary Completion Date : June 1, 2023
Estimated Study Completion Date : June 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Active rTMS
Single session of active cTBS (600 pulses, 40 seconds)
Device: Transcranial Magnetic Stimulation
Single session of continuous theta burst stimulation (cTBS) (a form of repetitive transcranial magnetic stimulation). cTBS involves application of bursts of three pulses of TMS at 50 Hz, repeated at intervals of 200ms for a total of 600 pulses (200 bursts).

Placebo Comparator: Sham rTMS
Single session of active cTBS (600 pulses, 40 seconds)
Device: Transcranial Magnetic Stimulation
Single session of continuous theta burst stimulation (cTBS) (a form of repetitive transcranial magnetic stimulation). cTBS involves application of bursts of three pulses of TMS at 50 Hz, repeated at intervals of 200ms for a total of 600 pulses (200 bursts).




Primary Outcome Measures :
  1. MEG [ Time Frame: Baseline, immediately before and after rTMS ]
    MEG Evoked fields (M100, MMF) and Spectral Power (Gamma)

  2. MRS [ Time Frame: Baseline, immediately before and after rTMS ]
    GABA+/Cr concentrations in the left pSTC

  3. DTI [ Time Frame: Baseline ]
    Diffusion tensor derived parameters in the auditory radiations and arcuate fasciculus

  4. fcMRI [ Time Frame: Baseline, immediately before and after rTMS ]
    BOLD correlations across pre-defined ROis


Secondary Outcome Measures :
  1. MEG [ Time Frame: Baseline, immediately before and after rTMS ]
    Inter-trial gamma-band coherence (ITC) and resting state alpha to gamma phase-amplitude coupling.

  2. Behavioral Measures [ Time Frame: Baseline ]
    SRS-2, CELF-5, EVT, PPVT, ADOS-2, ADI-R, VABS-III, WASI-II.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Pilot Phase

Inclusion criteria

  • Ability to provide informed consent
  • Age: 18-25 years
  • Must meet the definition of Healthy Control having completed the screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers or under protocol 17-M-0181, Recruitment and Characterization of Research Volunteers for NIMH Intramural Studies .

Main Study Phase

Inclusion criteria

  • Ability to provide informed assent and parent consent
  • Age: 14-17 years
  • Community Diagnosis of ASD based on DSM-IV or DSM-5 criteria
  • Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II). WASI-II will be used as a measure of intellectual function. Children will be included when FSIQ > 70.
  • Right-handed: to reduce heterogeneity.
  • Hearing: Normal hearing in order to complete the behavioural assessments.

EXCLUSION CRITERIA:

Participants will be screened to exclude individuals with co-occurring neurological or medical conditions that might confound the results, as well as to exclude subjects in whom MRI or rTMS might result in increased risk of side effects or complications. This accounts for the majority of the exclusion criteria listed:

Exclusion criteria

Participants will be screened to exclude individuals with neurological, psychological/behavioral or medical conditions, as well as to exclude subjects in whom MRI or rTMS might result in increased risk of side effects or complications. This accounts for the majority of the exclusion criteria listed:

Pilot Phase

  • Non-English Speakers
  • Known Neurological Disorder
  • Known Psychiatric Disorder
  • Known genetic disorder (e.g., NF1, tuberous sclerosis), acquired neurologic disease (e.g. stroke, tumour), cerebral palsy, history of severe head injury, intracranial pathology or significant dysmorphology;
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures;
  • History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy;
  • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.);
  • Metal implants (excluding dental fillings);
  • Pacemaker;
  • Implanted medication pump;
  • Vagal nerve stimulator;
  • Deep brain stimulator;
  • TENS unit (unless removed completely for the study);
  • Ventriculo-peritoneal shunt;
  • Signs of increased intracranial pressure;
  • Intracranial lesion (including incidental finding on MRI);
  • History of head injury resulting in prolonged loss of consciousness;
  • Pregnancy;
  • Participants who have received rTMS less than 7 days prior to enrollment;
  • Individuals taking GABAergic medications as well as any of the following drugs noted to have significant seizure threshold lowering potential: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline.
  • Individuals for whom it is not safe or appropriate to remain on a stable pharmacotherapy (for nonexclusionary medications) for six weeks prior to and over the course of their participation in the study.
  • A current NIMH employee or staff or their immediate family member.

Main Study Phase

  • Non-English Speakers
  • Known genetic disorder (e.g., NF1, tuberous sclerosis), acquired neurologic disease (e.g. stroke, tumour), cerebral palsy, history of severe head injury, intracranial pathology or significant dysmorphology;
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures;
  • History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy;
  • Any progressive (e.g., neurodegenerative) neurological disorder;
  • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.);
  • Metal implants (excluding dental fillings);
  • Pacemaker;
  • Implanted medication pump;
  • Vagal nerve stimulator;
  • Deep brain stimulator;
  • TENS unit (unless removed completely for the study);
  • Ventriculo-peritoneal shunt;
  • Signs of increased intracranial pressure;
  • Intracranial lesion (including incidental finding on MRI);
  • History of head injury resulting in prolonged loss of consciousness;
  • Pregnancy;
  • Participants who have received prior rTMS;
  • Active or History of psychosis, bipolar disorder bipolar disorder, active severe substance use disorders (within the last month), have active suicidal intent or plan as detected on screening instruments or in the investigator team s opinion is likely to attempt suicide within 6 months;
  • Individuals taking GABAergic medications as well as any of the following drugs noted to have significant seizure threshold lowering potential: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline.
  • Individuals for whom it is not safe or appropriate to remain on a stable pharmacotherapy (for nonexclusionary medications) for six weeks prior to and over the course of their participation in the study.
  • A current NIMH employee or staff or their immediate family member.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04798274


Contacts
Layout table for location contacts
Contact: Sarah H Lisanby, M.D. (301) 451-3029 lisanbysh@mail.nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov   
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Sarah H Lisanby, M.D. National Institute of Mental Health (NIMH)
Additional Information:
Layout table for additonal information
Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT04798274    
Other Study ID Numbers: 200159
20-M-0159
First Posted: March 15, 2021    Key Record Dates
Last Update Posted: August 19, 2021
Last Verified: June 29, 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):
GABA
Language
ASD
MEG
MRS
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders